ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Cash & Equivalents history
Currency unavailable · from the balance sheet
No Cash & Equivalents data reported for this period type.
Cash & Equivalents vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $544.59M USD | +124.0% | +89.5% | 93.3% | |
| Mar 2026 | $267.85M USD | — | — | 91.6% | |
| Mar 2026 | $211.38M USD | -2.6% | -16.2% | 86.1% | |
| Mar 2026 | $184.76M USD | +78.4% | +188.7% | 98.8% | |
| Mar 2026 | $155.66M USD | -43.4% | -9.5% | 35.1% | |
| Mar 2026 | €81.17M EUR | -43.2% | -0.9% | 81.9% | |
| Mar 2026 | $71.54M USD | +7.5% | -17.1% | 29.2% | |
| Mar 2026 | $64.11M USD | -30.2% | -30.5% | 21.8% | |
| Mar 2026 | $5.66M USD | -91.3% | -41.0% | 4.9% | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | -16.4% | -12.8% | 81.9% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.